Papers
3
Total Citations
7
H-Index
1
About
Alan Zwart is a radiation oncologist whose research centers on optimizing treatment for localized prostate cancer, particularly through stereotactic body radiation therapy (SBRT) and its combination with androgen deprivation therapy (ADT). His major contributions include demonstrating the feasibility and early outcomes of using SBRT as a less-invasive boost alternative to brachytherapy for unfavorable prostate cancer, as detailed in his most-cited work, “Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes” (5 citations). He has also investigated the quality-of-life impacts of treatment, notably characterizing bothersome hot flashes following neoadjuvant ADT and SBRT, and explored the understudied phenomenon of late radiation-related lymphopenia after prostate SBRT with or without pelvic irradiation. These studies, though early in citation count, address critical gaps in understanding both the efficacy and side-effect profiles of modern hypofractionated radiotherapy. Zwart’s work is notable for its focus on patient-reported outcomes and long-term toxicities, helping to refine treatment paradigms that balance cancer control with survivorship. His research is particularly valuable for clinicians and researchers seeking to personalize prostate cancer radiotherapy.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3